Maegim한국어

바이오솔루션

086820KOSDAQSector: Pharma & Biotech
₩5,830 3.55%Market cap ₩151.1BAs of Jul 21, 2026 close · updated once daily
D
Grade D36.2 ptsTop 76% of 2,523 stocks
Financial strength
31.5
Price attractiveness
41.5

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Growth momentum not rated — will be included automatically as data accumulates

1

Financial strength

31.5
How much debt does it carry relative to equity?
Debt-to-equity ratio
114.0%
Below median · Top 80.7% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
56.7%
Below median · Top 90% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-28.6%
Below median · Top 62.8% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
0.9%
Above median · Top 40.4% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original

3

Price attractiveness

41.5
Is the price expensive relative to earnings?
P/E (price-to-earnings)
552.8x
Above median · Top 41.3% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
4.72x
Below median · Top 75.8% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15